Two more recent studies from 2020 point to the ability of FDG-PET/CT scans to aid in treatment choice of certain newly approved therapies including tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI): there was good performance in predicting epidermal growth factor receptor (EGFR) mutation status in NSCLC cases, potentially providing a faster alternative method for EGFR target therapy choice (13, 14). This evidence concerns the gene EGFR and non-small cell lung carcinoma.